VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Pseudomonas aeruginosa

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
    4. Microbial Pathogenesis
    5. Host Ranges and Animal Models
    6. Host Protective Immunity
  2. Vaccine Related Pathogen Genes
    1. OprF (Protective antigen)
    2. OprI (Protective antigen)
    3. PcrV (Protective antigen)
    4. pilA (Protective antigen)
  3. Vaccine Information
    1. Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid (USDA: 4949.20)
    2. Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid (USDA: 4949.31)
    3. Mink Enteritis Killed Virus Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid (USDA: 49A5.20)
    4. Mink Enteritis Killed Virus Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid (USDA: 49A5.21)
    5. P. aeruginosa DNA Vaccine encoding OprF
    6. P. aeruginosa DNA vaccine pGACAG-OprF/OprI
    7. P. aeruginosa DNA vaccine pGACAG-OprF/OprI + pGACAG-PcrV + pGACAG-PilA
    8. P. aeruginosa DNA vaccine pGACAG-PcrV
    9. P. aeruginosa OprI Protein Vaccine
    10. P. aeruginosa PcrV Protein Vaccine
    11. SL3261-P. aeruginosa serogroup O11 O antigen
  4. References
I. General Information
1. NCBI Taxonomy ID:
287
2. Disease:
Pseudomonas aeruginosa infection
3. Introduction
Pseudomonas aeruginosa is member of the Gamma Proteobacteria class of Bacteria. It is a Gram-negative, aerobic rod belonging to the bacterial family Pseudomonadaceae. Since the revisionist taxonomy based on conserved macromolecules (e.g. 16S ribosomal RNA) the family includes only members of the genus Pseudomonas which are cleaved into eight groups. Pseudomonas aeruginosa is the type species of its group. which contains 12 other members. Pseudomonas aeruginosa is an opportunistic pathogen, meaning that it exploits some break in the host defenses to initiate an infection. In fact, Pseudomonas aeruginosa is the epitome of an opportunistic pathogen of humans. The bacterium almost never infects uncompromised tissues, yet there is hardly any tissue that it cannot infect if the tissue defenses are compromised in some manner. It causes urinary tract infections, respiratory system infections, dermatitis, soft tissue infections, bacteremia, bone and joint infections, gastrointestinal infections and a variety of systemic infections, particularly in patients with severe burns and in cancer and AIDS patients who are immunosuppressed. Pseudomonas aeruginosa infection is a serious problem in patients hospitalized with cancer, cystic fibrosis, and burns. The case fatality rate in these patients is near 50 percent (Textbook of Bacteriology).
4. Microbial Pathogenesis
P. aeruginosa infections are widely varied. The bacteria can colonize wounds and enter the blood stream, they can colonize the lungs, and they can also colonize the a scratched cornea. P. aeruginosa has a variety of virulence factors that contribute to its widely varied pathogenesis (Salyers and Whitt., 2002).
5. Host Ranges and Animal Models
Pseudomonas aeruginosa is an opportunistic human pathogen. The burned mouse model is used to model pseudomonas infection in burn patients. For lung infections guinea pig and rat models are used. C. elegans is also a model used to study host-pathogen interactions (Salyers and Whitt., 2002).
6. Host Protective Immunity
Most strains of P. aeruginosaare resistant to killing in serum alone, but the addition of polymorphonuclear leukocytes results in bacterial killing. Killing is most efficient in the presence of type-specific opsonizing antibodies, directed primarily at the antigenic determinants of LPS. This suggests that phagocytosis is an important defense and that opsonizing antibody is the principal functional antibody in protecting from P. aeruginosa infections. Once P. aeruginosa infection is established, other antibodies, such as antitoxin, may be important in controlling disease. Cell-mediated immunity does not seem to play a major role in resistance or defense against Pseudomonas infections (Textbook of Bacteriology).
1. OprF
  • Gene Name : OprF
  • Sequence Strain (Species/Organism) : Pseudomonas aeruginosa PAO1
  • VO ID : VO_0012360
  • NCBI Gene ID : 878442
  • NCBI Protein GI : 15596974
  • Locus Tag : PA1777
  • Genbank Accession : AF027290
  • Protein Accession : NP_250468
  • Taxonomy ID : 208964
  • Gene Starting Position : 1921173
  • Gene Ending Position : 1922225
  • Gene Strand (Orientation) : +
  • Protein Name : major porin and structural outer membrane porin OprF precursor
  • Protein pI : 4.75
  • Protein Weight : 34266.56
  • Protein Length : 350
  • DNA Sequence : Show Sequence
    >gi|110645304:1921173-1922225 Pseudomonas aeruginosa PAO1, complete genome
    GATGAAACTGAAGAACACCTTAGGCGTTGTCATCGGCTCGCTGGTTGCCGCTTCGGCAATGAACGCCTTT
    GCCCAGGGCCAGAACTCGGTAGAGATCGAAGCCTTCGGCAAGCGCTACTTCACCGACAGCGTTCGCAACA
    TGAAGAACGCGGACCTGTACGGCGGCTCGATCGGTTACTTCCTGACCGACGACGTCGAGCTGGCGCTGTC
    CTACGGTGAGTACCATGACGTTCGTGGCACCTACGAAACCGGCAACAAGAAGGTCCACGGCAACCTGACC
    TCCCTGGACGCCATCTACCACTTCGGTACCCCGGGCGTAGGTCTGCGTCCGTACGTGTCGGCTGGTCTGG
    CTCACCAGAACATCACCAACATCAACAGCGACAGCCAAGGCCGTCAGCAGATGACCATGGCCAACATCGG
    CGCTGGTCTGAAGTACTACTTCACCGAGAACTTCTTCGCCAAGGCCAGCCTCGACGGCCAGTACGGTCTG
    GAGAAGCGTGACAACGGTCACCAGGGCGAGTGGATGGCTGGCCTGGGCGTCGGCTTCAACTTCGGTGGTT
    CGAAAGCCGCTCCGGCTCCGGAACCGGTTGCCGACGTTTGCTCCGACTCCGACAACGACGGCGTTTGCGA
    CAACGTCGACAAGTGCCCGGATACCCCGGCCAACGTCACCGTTGACGCCAACGGCTGCCCGGCTGTCGCC
    GAAGTCGTACGCGTACAGCTGGACGTGAAGTTCGACTTCGACAAGTCCAAGGTCAAAGAGAACAGCTACG
    CTGACATCAAGAACCTGGCTGACTTCATGAAGCAGTACCCGTCCACTTCCACCACCGTTGAAGGTCACAC
    CGACTCCGTCGGCACCGACGCTTACAACCAGAAGCTGTCCGAGCGTCGTGCCAACGCCGTTCGTGACGTA
    CTGGTCAACGAGTACGGTGTAGAAGGTGGTCGCGTGAACGCTGTTGGTTACGGCGAGTCCCGCCCGGTTG
    CCGACAACGCCACCGCTGAAGGCCGCGCTATCAACCGTCGCGTTGAAGCCGAAGTAGAAGCTGAAGCCAA
    GTA
  • Protein Sequence : Show Sequence
    >gi|15596974|ref|NP_250468.1| major porin and structural outer membrane porin OprF precursor [Pseudomonas aeruginosa PAO1]
    MKLKNTLGVVIGSLVAASAMNAFAQGQNSVEIEAFGKRYFTDSVRNMKNADLYGGSIGYFLTDDVELALS
    YGEYHDVRGTYETGNKKVHGNLTSLDAIYHFGTPGVGLRPYVSAGLAHQNITNINSDSQGRQQMTMANIG
    AGLKYYFTENFFAKASLDGQYGLEKRDNGHQGEWMAGLGVGFNFGGSKAAPAPEPVADVCSDSDNDGVCD
    NVDKCPDTPANVTVDANGCPAVAEVVRVQLDVKFDFDKSKVKENSYADIKNLADFMKQYPSTSTTVEGHT
    DSVGTDAYNQKLSERRANAVRDVLVNEYGVEGGRVNAVGYGESRPVADNATAEGRAINRRVEAEVEAEAK
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : The oprF gene was cloned into plasmid vector pVR1020, and the plasmid vaccines were delivered to mice by biolistic (gene gun) intradermal inoculation. Following the initial immunization and two consecutive boosts, each at 2-week intervals, protection was demonstrated in a mouse model of chronic pulmonary infection by P. aeruginosa. Eight days postchallenge, both lungs were removed and examined. A significant reduction in the presence of severe macroscopic lesions, as well as in the number of bacteria present in the lungs, was seen (Price et al., 2001).
  • Related Vaccine(s): P. aeruginosa DNA Vaccine encoding OprF , P. aeruginosa DNA vaccine pGACAG-OprF/OprI , P. aeruginosa DNA vaccine pGACAG-OprF/OprI + pGACAG-PcrV + pGACAG-PilA
2. OprI
  • Gene Name : OprI
  • Sequence Strain (Species/Organism) : Pseudomonas aeruginosa PAO1
  • VO ID : VO_0012362
  • NCBI Gene ID : 879851
  • NCBI Protein GI : 15598049
  • Locus Tag : PA2853
  • Genbank Accession : AE004091
  • Protein Accession : NP_251543
  • Taxonomy ID : 208964
  • Gene Starting Position : 3206914
  • Gene Ending Position : 3207165
  • Gene Strand (Orientation) : +
  • Protein Name : Outer membrane lipoprotein OprI precursor
  • Protein pI : 8.51
  • Protein Weight : 8635.98
  • Protein Length : 83
  • DNA Sequence : Show Sequence
    >gi|110645304:3206914-3207165 Pseudomonas aeruginosa PAO1, complete genome
    GATGAACAACGTTCTGAAATTCTCTGCTCTGGCTCTGGCTGCTGTTCTGGCCACCGGTTGCAGCAGCCAC
    TCCAAAGAAACCGAAGCTCGTCTGACCGCTACCGAAGACGCAGCTGCTCGTGCTCAGGCTCGCGCTGACG
    AAGCCTATCGCAAGGCTGACGAAGCTCTGGGCGCTGCTCAGAAAGCTCAGCAGACTGCTGACGAGGCTAA
    CGAGCGTGCCCTGCGCATGCTGGAAAAAGCCAGCCGCAAGTA
  • Protein Sequence : Show Sequence
    >gi|15598049|ref|NP_251543.1| Outer membrane lipoprotein OprI precursor [Pseudomonas aeruginosa PAO1]
    MNNVLKFSALALAAVLATGCSSHSKETEARLTATEDAAARAQARADEAYRKADEALGAAQKAQQTADEAN
    ERALRMLEKASRK
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Recombinant OprI protein was used to immunize mice, and was found to be protective against a challenge with a four- to fivefold 50% lethal dose of P. aeruginosa (Finke et al., 1990).
  • Related Vaccine(s): P. aeruginosa DNA vaccine pGACAG-OprF/OprI , P. aeruginosa DNA vaccine pGACAG-OprF/OprI + pGACAG-PcrV + pGACAG-PilA , P. aeruginosa OprI Protein Vaccine
3. PcrV
  • Gene Name : PcrV
  • Sequence Strain (Species/Organism) : Pseudomonas aeruginosa PAO1
  • VO ID : VO_0012361
  • NCBI Gene ID : 882997
  • NCBI Protein GI : 15596903
  • Locus Tag : PA1706
  • Genbank Accession : AE004091
  • Protein Accession : NP_250397
  • Taxonomy ID : 208964
  • Gene Starting Position : 1852287
  • Gene Ending Position : 1853171
  • Gene Strand (Orientation) : +
  • Protein Name : type III secretion protein PcrV
  • Protein pI : 4.77
  • Protein Weight : 30496.99
  • Protein Length : 294
  • DNA Sequence : Show Sequence
    >gi|110645304:1852287-1853171 Pseudomonas aeruginosa PAO1, complete genome
    GATGGAAGTCAGAAACCTTAATGCCGCTCGCGAGCTGTTCCTGGACGAGCTCCTGGCCGCGTCGGCGGCG
    CCTGCCAGTGCCGAGCAGGAGGAACTGCTGGCCCTGTTGCGCAGCGAGCGGATCGTGCTGGCCCACGCCG
    GCCAGCCGCTGAGCGAGGCGCAAGTGCTCAAGGCGCTCGCCTGGTTGCTCGCGGCCAATCCGTCCGCGCC
    TCCGGGGCAGGGCCTCGAGGTACTCCGCGAAGTCCTGCAGGCACGTCGGCAGCCCGGTGCGCAGTGGGAT
    CTGCGCGAGTTCCTGGTGTCGGCCTATTTCAGCCTGCACGGGCGTCTCGACGAGGATGTCATCGGTGTCT
    ACAAGGATGTCCTGCAGACCCAGGACGGCAAGCGCAAGGCGCTGCTCGACGAGCTCAAGGCGCTGACCGC
    GGAGTTGAAGGTCTACAGCGTGATCCAGTCGCAGATCAACGCCGCGCTGTCGGCCAAGCAGGGCATCAGG
    ATCGACGCTGGCGGTATCGATCTGGTCGACCCCACGCTATATGGCTATGCCGTCGGCGATCCCAGGTGGA
    AGGACAGCCCCGAGTATGCGCTGCTGAGCAATCTGGATACCTTCAGCGGCAAGCTGTCGATCAAGGATTT
    TCTCAGCGGCTCGCCGAAGCAGAGCGGGGAACTCAAGGGCCTCAGCGATGAGTACCCCTTCGAGAAGGAC
    AACAACCCGGTCGGCAATTTCGCCACCACGGTGAGCGACCGCTCGCGTCCGCTGAACGACAAGGTCAACG
    AGAAGACCACCCTGCTCAACGACACCAGCTCCCGCTACAACTCGGCGGTCGAGGCGCTCAACCGCTTCAT
    CCAGAAATACGACAGCGTCCTGCGCGACATTCTCAGCGCGATCTA
  • Protein Sequence : Show Sequence
    >gi|15596903|ref|NP_250397.1| type III secretion protein PcrV [Pseudomonas aeruginosa PAO1]
    MEVRNLNAARELFLDELLAASAAPASAEQEELLALLRSERIVLAHAGQPLSEAQVLKALAWLLAANPSAP
    PGQGLEVLREVLQARRQPGAQWDLREFLVSAYFSLHGRLDEDVIGVYKDVLQTQDGKRKALLDELKALTA
    ELKVYSVIQSQINAALSAKQGIRIDAGGIDLVDPTLYGYAVGDPRWKDSPEYALLSNLDTFSGKLSIKDF
    LSGSPKQSGELKGLSDEYPFEKDNNPVGNFATTVSDRSRPLNDKVNEKTTLLNDTSSRYNSAVEALNRFI
    QKYDSVLRDILSAI
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Burned Pseudomonas aeruginosa-infected mice immunized against PcrV, a type III virulence system translocating protein, showed significantly enhanced survival compared to controls (Holder et al., 2001).
  • Related Vaccine(s): P. aeruginosa DNA vaccine pGACAG-OprF/OprI + pGACAG-PcrV + pGACAG-PilA , P. aeruginosa DNA vaccine pGACAG-PcrV , P. aeruginosa PcrV Protein Vaccine
4. pilA
  • Gene Name : pilA
  • Sequence Strain (Species/Organism) : Pseudomonas aeruginosa PAO1
  • NCBI Protein GI : 15599721
  • Other Database IDs : CDD:227304
    CDD:215727
  • Taxonomy ID : 208964
  • Gene Strand (Orientation) : ?
  • Protein Name : type 4 fimbrial PilA
  • Protein Note : Tfp pilus assembly protein, major pilin PilA [Cell motility and secretion / Intracellular trafficking and secretion]; COG4969
  • Protein Sequence : Show Sequence
    >gi|15599721|ref|NP_253215.1| type 4 fimbrial PilA [Pseudomonas aeruginosa PAO1]
    MKAQKGFTLIELMIVVAIIGILAAIAIPQYQNYVARSEGASALATINPLKTTVEESLSRGIAGSKIKIGT
    TASTATETYVGVEPDANKLGVIAVAIEDSGAGDITFTFQTGTSSPKNATKVITLNRTADGVWACKSTQDP
    MFTPKGCDN
  • Molecule Role : Protective antigen
  • Related Vaccine(s): P. aeruginosa DNA vaccine pGACAG-OprF/OprI + pGACAG-PcrV + pGACAG-PilA
III. Vaccine Information
1. Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid (USDA: 4949.20)
a. Manufacturer:
Intervet Inc.
b. Vaccine Ontology ID:
VO_0001834
c. Type:
Live, attenuated vaccine; Inactivated or "killed" vaccine
d. Status:
Licensed
e. Location Licensed:
USA
f. Host Species for Licensed Use:
Carnivores
2. Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid (USDA: 4949.31)
a. Manufacturer:
United Vaccines, Inc.
b. Vaccine Ontology ID:
VO_0001835
c. Type:
Live, attenuated vaccine; Inactivated or "killed" vaccine
d. Status:
Licensed
e. Location Licensed:
USA
f. Host Species for Licensed Use:
Carnivores
3. Mink Enteritis Killed Virus Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid (USDA: 49A5.20)
a. Manufacturer:
Intervet Inc.
b. Vaccine Ontology ID:
VO_0001839
c. Type:
Inactivated or "killed" vaccine
d. Status:
Licensed
e. Location Licensed:
USA
f. Host Species for Licensed Use:
Carnivores
4. Mink Enteritis Killed Virus Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid (USDA: 49A5.21)
a. Manufacturer:
United Vaccines, Inc.
b. Vaccine Ontology ID:
VO_0001840
c. Type:
Inactivated or "killed" vaccine
d. Status:
Licensed
e. Location Licensed:
USA
f. Host Species for Licensed Use:
Carnivores
5. P. aeruginosa DNA Vaccine encoding OprF
a. Vaccine Ontology ID:
VO_0004189
b. Type:
DNA vaccine
c. Status:
Research
d. Antigen
The pVR1020/oprF plasmid.
e. Gene Engineering of OprF
  • Type: DNA vaccine construction
  • Description: The 977-bp oprF gene was cloned from P. aeruginosa PAO1 genomic DNA into the eukaryotic expression plasmid pVR1020 (Price et al., 2001).
  • Detailed Gene Information: Click here.
f. Vector:
pVR1020
g. Immunization Route
abdomen gene gun
h. Mouse Response
  • Host Strain: Pathogen Free ICR
  • Vaccination Protocol: At 14-day intervals, groups of 30 mice were inoculated a total of three times in the abdomen via biolistic particle injection (Helios Gene Gun kit; Bio-Rad, Richmond, Calif.) on days 0, 14, and 28 with 2 μg of either pVR1020 (control) or pVR1020/oprF, which was used to coat 1-μm-diameter gold beads (Price et al., 2001).
  • Challenge Protocol: Two weeks after the final immunization, the mice were challenged with agar beads containing the P. aeruginosa FD immunotype 4 strain. The mice were first anesthetized with an intraperitoneal injection of sodium pentobarbital and then inoculated via a tracheal incision with 50 μl of an agar bead slurry encasing approximately 7 × 102 CFU of P. aeruginosa (Price et al., 2001).
  • Efficacy: A significant reduction in the presence of severe macroscopic lesions, as well as in the number of bacteria present in the lungs, was seen in immunized mice (Price et al., 2001).
  • Description: The immunoprotective potential of the pVR1020/oprF vaccine was tested in a mouse model of chronic pulmonary infection (Price et al., 2001).
6. P. aeruginosa DNA vaccine pGACAG-OprF/OprI
a. Vaccine Ontology ID:
VO_0004570
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of OprF
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of OprI
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Vector:
pGACAG (Saha et al., 2006)
h. Immunization Route
intramuscular electroporation
i. Mouse Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Monovalent DNA vaccination targeting OprF/OprI could protect 80% of mice 4 days p.i. On the other hand, 70% of mice immunized with the control plasmid, PilA vaccine, or multivalent vaccine via GG were dead within 5 days p.i. (p < 0.01) (Saha et al., 2006).
7. P. aeruginosa DNA vaccine pGACAG-OprF/OprI + pGACAG-PcrV + pGACAG-PilA
a. Vaccine Ontology ID:
VO_0004572
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of OprF
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of OprI
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Gene Engineering of PcrV
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
h. Gene Engineering of pilA
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
i. Vector:
pGACAG (Saha et al., 2006)
j. Immunization Route
intramuscular electroporation
k. Mouse Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: All mice vaccinated with multivalent DNA via imEPT survived for more than 10 days p.i. with PAK. On the other hand, 70% of mice immunized with the control plasmid, PilA vaccine, or multivalent vaccine via GG were dead within 5 days p.i. (p < 0.01) (Saha et al., 2006).
8. P. aeruginosa DNA vaccine pGACAG-PcrV
a. Vaccine Ontology ID:
VO_0004571
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of PcrV
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Vector:
pGACAG (Saha et al., 2006)
g. Immunization Route
intramuscular electroporation
h. Mouse Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Monovalent DNA vaccination targeting PcrV could protect 80% of mice 4 days p.i. On the other hand, 70% of mice immunized with the control plasmid, PilA vaccine, or multivalent vaccine via GG were dead within 5 days p.i. (p < 0.01) (Saha et al., 2006).
9. P. aeruginosa OprI Protein Vaccine
a. Vaccine Ontology ID:
VO_0004190
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
Recombinant OprI protein
e. Gene Engineering of OprI
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
f. Adjuvant: aluminum hydroxide vaccine adjuvant
  • VO ID: VO_0000127
  • Description: 100 μl of 1.5% Al(OH)3 (Finke et al., 1990).
g. Immunization Route
Intraperitoneal injection (i.p.)
h. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: Female BALB/c mice, 12 to 16 weeks old, received 100 μl (27 ,ug) of OprI suspended in 100 μl of 1.5% Al(OH)3 intraperitoneally on days 0, 14, 35, and 63. Controls received Al(OH)3 only (Finke et al., 1990).
  • Challenge Protocol: mice were challenged intraperitoneally 10 days after the last immunization with 200 μl of a P. aeruginosa serogroup 6 suspension. Mice vaccinated with recombinant OprI received 6 x 106 to 1 x 108 living organisms each. (Finke et al., 1990).
  • Efficacy: Recombinant OprI protein was used to immunize mice, and was found to be protective against a challenge with a four- to fivefold 50% lethal dose of P. aeruginosa (Finke et al., 1990).
10. P. aeruginosa PcrV Protein Vaccine
a. Vaccine Ontology ID:
VO_0004191
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
PcrV
e. Gene Engineering of PcrV
  • Type: Recombinant protein preparation
  • Description: PcrV was produced as a lipopolysaccharide-free histidine-tagged infusion protein in pET16b and was purified by nickel chromatography (Holder et al., 2001).
  • Detailed Gene Information: Click here.
f. Adjuvant: incomplete Freunds adjuvant
  • VO ID: VO_0000142
  • Description: 0.1 ml of incomplete Freund's adjuvant (Holder et al., 2001).
g. Immunization Route
Intramuscular injection (i.m.)
h. Mouse Response
  • Host Strain: CF-1
  • Vaccination Protocol: On day 0, groups of 10 female CF-1 mice weighing 22 to 25 g were immunized intramuscularly in the hind leg (10 μg of immunogen in 0.1 ml of incomplete Freund's adjuvant), followed by a booster dose (10 μg in saline) without adjuvant on day 14 (Holder et al., 2001).
  • Challenge Protocol: Using the burned mouse model, mice were challenged by one of three strains of P. aeruginosa (Holder et al., 2001).
  • Efficacy: Burned Pseudomonas aeruginosa-infected mice immunized against PcrV, a type III virulence system translocating protein, showed significantly enhanced survival compared to controls (Holder et al., 2001).
11. SL3261-P. aeruginosa serogroup O11 O antigen
a. Vaccine Ontology ID:
VO_0004674
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
Attenuated Salmonella enterica serovar Typhimurium SL3261 expressing P. aeruginosa serogroup O11 O antigen (DiGiandomenico et al., 2004).
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Vaccination Protocol: For oral vaccination, mice were fed 100 μl of either PBS or the Salmonella vector and vaccine strains (1 × 109 to 5 × 109 CFU) by intragastric gavage. Oral inoculation was repeated once per week for a total of 4 weeks. For i.p. vaccination, mice were inoculated with a single dose of either PBS or each Salmonella strain (106 CFU) (DiGiandomenico et al., 2004).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Mice were challenged with P. aeruginosa strains 9882-80 (serogroup O11) and 6294 (serogroup O6) (DiGiandomenico et al., 2004).
  • Efficacy: Orally vaccinated mice with an O11 strain (9882-80) at 6 and 12 times the 50% lethal dose showed increased survival in mice that received the vaccine compared to phosphate-buffered saline (PBS)- and vector-treated controls; no difference in survival was seen with a heterologous strain, 6294 (serogroup O6). In addition, significant protection against 9882-80 was not observed in i.p. vaccinated animals (DiGiandomenico et al., 2004).
IV. References
1. Finke et al., 1990: Finke M, DuchĂȘne M, Eckhardt A, Domdey H, von Specht BU. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli. Infection and immunity. 1990; 58(7); 2241-2244. [PubMed: 2114360].
2. Holder et al., 2001: Holder IA, Neely AN, Frank DW. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infection and immunity. 2001; 69(9); 5908-5910. [PubMed: 11500471].
3. Price et al., 2001: Price BM, Galloway DR, Baker NR, Gilleland LB, Staczek J, Gilleland HE Jr. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa. Infection and immunity. 2001; 69(5); 3510-3515. [PubMed: 11292786].
4. Saha et al., 2006: Saha S, Takeshita F, Sasaki S, Matsuda T, Tanaka T, Tozuka M, Takase K, Matsumoto T, Okuda K, Ishii N, Yamaguchi K, Klinman DM, Xin KQ, Okuda K. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine. 2006; 24(37-39); 6240-6249. [PubMed: 16806598].
5. Salyers and Whitt., 2002: Abigail A. Salyers, Dixie D. Whitt. Pseudomonas aeruginosa and Related Species, a Lesson in Versatility. 247-62. Bacterial Pathogenesis: A Molecular Approach. 2002. ASM Press, Washington D.C. USA.
6. Textbook of Bacteriology: Pseudomonas [http://www.textbookofbacteriology.net/pseudomonas.html]
7. Zaidi et al., 2006: Zaidi TS, Priebe GP, Pier GB. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infection and immunity. 2006; 74(2); 975-983. [PubMed: 16428743].